Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice.

Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC.

J Virol. 2011 Feb;85(4):1420-8. doi: 10.1128/JVI.01926-10. Epub 2010 Nov 24.

2.

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.

Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP, Martin DE, Nitz TJ, Wild CT, Freed EO.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7. doi: 10.1128/AAC.02121-15.

3.

Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.

Lin Z, Cantone J, Lu H, Nowicka-Sans B, Protack T, Yuan T, Yang H, Liu Z, Drexler D, Regueiro-Ren A, Meanwell NA, Cockett M, Krystal M, Lataillade M, Dicker IB.

PLoS Pathog. 2016 Nov 28;12(11):e1005990. doi: 10.1371/journal.ppat.1005990. eCollection 2016 Nov.

4.

The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.

Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.

Retrovirology. 2011 Dec 7;8:101. doi: 10.1186/1742-4690-8-101.

5.

Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.

Margot NA, Gibbs CS, Miller MD.

Antimicrob Agents Chemother. 2010 Jun;54(6):2345-53. doi: 10.1128/AAC.01784-09. Epub 2010 Mar 22.

6.

Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.

Waki K, Durell SR, Soheilian F, Nagashima K, Butler SL, Freed EO.

PLoS Pathog. 2012;8(11):e1002997. doi: 10.1371/journal.ppat.1002997. Epub 2012 Nov 8.

7.

Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.

Fontana J, Keller PW, Urano E, Ablan SD, Steven AC, Freed EO.

J Virol. 2015 Nov 4;90(2):972-8. doi: 10.1128/JVI.02204-15.

8.

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.

Adamson CS, Sakalian M, Salzwedel K, Freed EO.

Retrovirology. 2010 Apr 20;7:36. doi: 10.1186/1742-4690-7-36.

9.

A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.

Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F.

Antimicrob Agents Chemother. 2011 Jul;55(7):3324-9. doi: 10.1128/AAC.01435-10. Epub 2011 Apr 18.

10.

The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO.

Virology. 2010 Apr 25;400(1):137-44. doi: 10.1016/j.virol.2010.01.028. Epub 2010 Feb 20.

11.

A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition.

Keller PW, Huang RK, England MR, Waki K, Cheng N, Heymann JB, Craven RC, Freed EO, Steven AC.

J Virol. 2013 Dec;87(24):13655-64. doi: 10.1128/JVI.01408-13. Epub 2013 Oct 9.

12.

Structural analysis of HIV-1 maturation using cryo-electron tomography.

de Marco A, Müller B, Glass B, Riches JD, Kräusslich HG, Briggs JA.

PLoS Pathog. 2010 Nov 24;6(11):e1001215. doi: 10.1371/journal.ppat.1001215.

13.

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.

J Virol. 2006 Nov;80(22):10957-71. Epub 2006 Sep 6.

14.

Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO.

J Virol. 2009 May;83(10):4884-94. doi: 10.1128/JVI.02659-08. Epub 2009 Mar 11.

15.

Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Kräusslich HG.

J Virol. 1998 Apr;72(4):2846-54.

16.

Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ.

Antimicrob Agents Chemother. 2009 May;53(5):2185-8. doi: 10.1128/AAC.01650-08. Epub 2009 Feb 17.

17.

Cryo-electron microscopy of tubular arrays of HIV-1 Gag resolves structures essential for immature virus assembly.

Bharat TA, Castillo Menendez LR, Hagen WJ, Lux V, Igonet S, Schorb M, Schur FK, Kräusslich HG, Briggs JA.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8233-8. doi: 10.1073/pnas.1401455111. Epub 2014 May 19.

18.

Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells.

Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, Sundquist WI, Jensen GJ.

EMBO J. 2007 Apr 18;26(8):2218-26. Epub 2007 Mar 29.

19.

Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid.

Meng X, Zhao G, Yufenyuy E, Ke D, Ning J, Delucia M, Ahn J, Gronenborn AM, Aiken C, Zhang P.

PLoS Pathog. 2012;8(8):e1002886. doi: 10.1371/journal.ppat.1002886. Epub 2012 Aug 23.

20.

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

Fun A, van Maarseveen NM, Pokorná J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M.

Retrovirology. 2011 Aug 24;8:70. doi: 10.1186/1742-4690-8-70.

Supplemental Content

Support Center